Just been prescribed this drug by my doctor, to treat my angina, yet one more drug to take along with my 10 others a day.
Isosorbide mononitrate is used for the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina.
Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur, and marketed in the UK under the trade names: Monosorb, Chemydur. In India this drug is available under the brand names of Ismo, Monotrate, Solotrate, and Monit.
Isosorbide mononitrate
Looking at the side effects, I can confirm the headaches, nausea and dizziness, but I also get cold sweats from it.
Side effects :
The adverse reactions which follow have been reported in studies with isosorbide mononitrate:
Very common: Headache predominates (up to 30%) necessitating withdrawal of 2 to 3 % of patients, but the incidence reduces rapidly as treatment continues .
Common: Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%).
Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment.
Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. These symptoms generally disappear during long-term treatment.
Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn.
Oh well, one more pill won’t kill me, hopefully.
- Similar posts
- Ivabradine cuts the risk of heart failure by 26% (21%)
- Lorcaserin diet pill trial (14.4%)
- Low blood pressure (12.8%)
- Cardiac arrest - sick sinus syndrome - research breakthrough (12.6%)
- Chronic fatigue syndrome (CFS) linked to retrovirus (12.6%)
ASTRAZENECA yesterday got the green light from regulators for the launch of a new heart medicine, as rival GlaxoSmithKline faced up to a clampdown on sales of its diabetes treatment.
The European Medicines Agency said it had recommended approval of AstraZeneca’s blood thinning treatment Brilinta, used to treat dangerous clots.
It is now subject to final approval by the European Commission and could be in use in Europe and the UK by spring 2011.
Brilinta, which will be sold as Brilique in Europe, has yet to be approved in the US where the Food and Drug Administration has delayed the results of its review by three months until mid-December.
Analysts believe the drug could become a so-called blockbuster, with sales set to reach more than £1billion by 2014. It is a competitor to Plavix, the world’s second biggest selling drug, made by Sanofi-Aventis and Bristol-Myers Squibb.
http://www.express.co.uk/posts/view/201657/AstraZeneca-upbeat-on-heart-drug-green-light
Proposals to give free prescriptions to people in England with long-term conditions have been put on hold due to financial pressures on the NHS.
Health minister Simon Burns said a decision on prescription charges and exemptions cannot be made before the spending review due in the autumn.
Plans for expanding eligibility for free prescriptions were first announced by Gordon Brown in 2008.
All charges have been scrapped in Wales and are being phased out in Scotland.
In England, prescription charges for cancer patients have already been dropped.
http://news.bbc.co.uk/1/hi/health/10170876.stm